Uriel Sinai/ Getty Images
For decades, marijuana has been listed as a “Schedule I” drug—on par with heroin.
The U.S. Drug Enforcement
Administration on Thursday denied requests to stop classifying marijuana
as a dangerous drug with no medical use, leaving users and businesses
in limbo after many states have legalized it for medical or recreational
purposes.
The DEA though did relax certain restrictions on growing marijuana for research purposes.
For decades, marijuana has been listed as
a “Schedule I” drug, placing it on par with heroin. The government has
repeatedly rejected appeals for reclassification.
“Marijuana shouldn’t be listed as
Schedule I,” U.S. Representative Earl Blumenauer, a Democrat from
Oregon, said in a statement. He said the decision left “patients and
marijuana businesses trapped between state and federal laws.”
Thursday’s DEA decision was a response to
a 2011 petition by two former state governors who had urged federal
agencies to re-classify marijuana as a drug with accepted medical uses.
In a letter to the petitioners, the DEA
said it had asked the Department of Health and Human Services for a
scientific and medical evaluation.
“HHS concluded that marijuana has a high
potential for abuse, has no accepted medical use in the United States,
and lacks an acceptable level of safety for use even under medical
supervision,” the letter said.
That assessment comes amid statistics
showing zero overdose deaths due to marijuana each year at a time of an
alarming rise of heroin-related deaths in the United States as
politicians debate remedies for exploding opioid abuse.
Twenty-five states have sanctioned some
forms of marijuana use for medical purposes. Alaska, Washington, Oregon,
Colorado and the District of Columbia now allow recreational use for
adults, while California and eight other states have recreational or
medical marijuana proposals headed for their 2016 ballots.
On Thursday, Arizona became the latest
state to certify a ballot initiative to legalize recreational marijuana
for its November ballot.
The position of the U.S. government on
marijuana has impacts for states that have legalized its recreational or
medical use. Doctors and businesses growing, selling or prescribing
cannabis may be operating legally within a given state but still acting
in opposition to federal law, risking arrest and sanctions.
Legal marijuana businesses have
difficulty finding banks that will work with them, also due to concerns
about breaking federal law.
Some experts have argued that medical marijuana could help cut opioid use.
Taylor West, deputy director of the
National Cannabis Industry Association, said the DEA’s decision would
curtail research since marijuana would remain a criminal product.
“Research institutions are going to be
somewhat hesitant if they think they will potentially jeopardize other
research funding,” she said. “This decision by the DEA really flies in
the face of objective science.”
Smart Approaches to Marijuana, an
alliance of doctors, policy makers and treatment professionals who
oppose legalization, took a different view.
“I think it was a balanced decision and isn’t surprising to the scientific community,” said President Kevin Sabat.
Meanwhile, the DEA will allow more
growers to apply for certification by the agency to help supply
researchers “with a more varied and robust supply of marijuana.” Now the
University of Mississippi is the lone such supplier.
Britain’s GW Pharmaceuticals
, which is developing a promising cannabis-derived epilepsy
treatment, has said it will take longer to reach the U.S. market even
with Food and Drug Administration approval because it would then have to
be separately rescheduled by the DEA.
No comments:
Post a Comment